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Abstract
Background: Air pollution is a major risk factor for cardiovascular disease, of which ozone is a major contributor. Several
studies have found associations between ozone and cardiovascular morbidity, but the results have been inconclusive. We
investigated associations between ozone and changes across biological pathways associated with cardiovascular disease.
Methods: Using a panel study design, 13 participants with coronary artery disease were assessed for markers of systemic
inflammation, heart rate variability and repolarization, lipids, blood pressure, and endothelial function. Daily measurements
of ozone and particulate matter (PM2.5) were obtained from central monitoring stations. Single (ozone) and two-pollutant
(ozone and PM2.5) models were used to assess percent changes in measurements per interquartile ranges of pollutants.
Results: Per interquartile increase in ozone, changes in tissue plasminogen factor (6.6%, 95% confidence intervals (CI) = 0.
4, 13.2), plasminogen activator inhibitor-1 (40.5%, 95% CI = 8.7, 81.6), neutrophils (8.7% 95% CI = 1.5, 16.4), monocytes (10.
2%, 95% CI = 1.0, 20.1), interleukin-6 (15.9%, 95% CI = 3.6, 29.6), large-artery elasticity index (−19.5%, 95% CI = −34.0, −1.7),
and the baseline diameter of the brachial artery (−2.5%, 95% CI = −5.0, 0.1) were observed. These associations were
robust in the two-pollutant model.
Conclusions: We observed alterations across several pathways associated with cardiovascular disease in 13 coronary
artery disease patients following ozone exposures, independent of PM2.5. The results support the biological plausibility
of ozone-induced cardiovascular effects. The effects were found at concentrations below the EPA National Ambient Air
Quality Standards for both ozone and PM2.5.
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Background
Air pollution is a major and independent environmental
risk factor for cardiovascular disease [1]. Epidemiological
studies suggest that the strongest associations are
between particulate matter (PM) and cardiovascular
morbidity and mortality [2, 3]; however, recent work
suggests that ozone also may be associated with negative
cardiovascular health effects including coronary death,
cardiac arrest, and ischemic stroke [4–6]. To clarify
some contrary findings [7, 8] and establish biological
plausibility, work is needed to establish potential mecha-
nisms mediating ozone’s adverse cardiovascular health
effects [9].
Clinical and toxicological studies have established several
possible mechanisms by which PM adversely impacts the
cardiovascular system, thus providing biologic plausibility
for the epidemiologic studies; similar approaches have
begun to be used with ozone using controlled human
exposure studies. Under controlled conditions, increases
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in systemic pro-inflammatory markers were observed in
26 healthy human participants following exposures to
ozone and clean air [10, 11]. In addition, researchers have
found changes in fibrinolysis markers such as plasminogen
activator inhibitor-1, plasminogen, and D-dimer, when
young healthy participants were exposed to ozone [11, 12].
Further, researchers have begun looking at changes in car-
diovascular biomarkers in larger epidemiological work to
support associations between ozone exposure and cardio-
vascular morbidity and mortality. In 1536 people living in
Stockholm, changes in fibrinogen were associated with
short-term ambient ozone exposures [13]. Blood pressure,
platelet activation markers, and arterial stiffness were also
found to be altered with ozone exposures in healthy adults
living in China [14]. Additional research of men participat-
ing in the Normative Aging Study found changes in heart
rate variability parameters with exposures to ambient
ozone levels [15].
Some populations may experience enhanced adverse air
pollutant-associated health effects: children, the elderly,
the obese, and those with underlying disease. In studies of
subjects with a concurrent history of cardiovascular
disease, air pollution exposure has been associated with
greater inflammation, coagulation, and decreases in heart
rate variability [16, 17]. In our previously conducted work
in a cohort of coronary artery disease (CAD) patients,
ambient ozone exposure was associated with changes in
plasma metabolite levels [18]. This work suggests that
metabolic processes may contribute to or mediate cardio-
vascular outcomes due to air pollutant exposure.
In order to expand upon this work we undertook a
detailed panel study to assess whether there are alterations
in several critical cardiovascular disease-associated bio-
logical pathways associated with acute ozone exposures.
We recruited 13 volunteers with CAD to assess whether
changes in endothelial function, fibrinolysis, inflammation,
lipids, heart rate variability, and repolarization are ob-
served following acute ozone exposure. In the interest of
studying the effects of ozone in the context of particulate
matter with a diameter of less than 2.5 μm (PM2.5) and to
address potential confounding, we used a two-pollutant
model to control for PM concentrations collected from
central monitoring stations [19]. The results of this work
may provide biological plausibility in support of the con-
cept that ozone induces adverse cardiovascular effects in
susceptible populations.
Methods
Study population and design
The source population for this study was the Duke
University Medical Center CATHeterization GENetics
(CATHGEN) cohort of nearly 10,000 individuals [20].
Duke University is located in central North Carolina in
the city of Durham. To participate in CATHGEN,
patients were between 40 and 75 years of age and had
undergone a cardiac catheterization between 2001 and
2010 at a Duke University Hospital.
Starting with residents that resided within a reasonable
commuting distance to the U.S. Environmental Protec-
tion Agency’s Human Studies Facility in Chapel Hill,
NC, 448 letters were mailed out to participants enrolled
in CATHGEN. The only exclusion criterion for not
receiving a letter of invitation to participate was unstable
angina and congestive heart failure. Fifty-four partici-
pants responded to the mailed letters. Of those, 15 par-
ticipants meeting the severity criteria were enrolled for
the current study. These volunteers were required to
have a stable clinical status, documented coronary artery
disease (> 75 occlusion in one major coronary vessel), a
stable medication regimen over 3 months prior to
enrollment, and an electrocardiogram demonstrating
normal sinus rhythm. Exclusion criteria for the current
study also included hematocrit < 34%, current smoking
or smoking history within 1 year of study (defined as
more than one pack of cigarettes in the past year),
sustained cardiac arrhythmias, presence of a pacemaker
or implanted cardioverter-defibrillator, systolic blood
pressure (SBP) ≥ 150 mmHg or ≤ 90 mmHg or diastolic
blood pressure (DBP) ≥ 100 mmHg, known vascular
obstruction of the upper extremities, unstable angina,
moderate to severe chronic pulmonary disease (as deter-
mined by spirometry demonstrating < 60% predicted
value for forced vital capacity (FVC) or forced expiratory
volume in 1s (FEV1) and including chronic obstructive
pulmonary disease, pulmonary fibrosis, moderate to
severe asthma, aortic stenosis), recent (past 6 months)
myocardial infarction, cerebrovascular accident (i.e.
stroke) or admission for heart failure, recent (past
6 months) vascular intervention/bypass surgery, or
current pregnancy. Participants were also asked to re-
frain from vigorous exercise on study mornings and
would be temporarily excluded from participation if they
experienced a respiratory tract infection within the pre-
ceding 4 weeks or had a recent or recurring exposure to
pollutants or irritants. All medications were evaluated by
the study physician.
Each participant visited the U.S. Environmental Protec-
tion Agency’s Human Studies Facility for two consecutive
days for up to 10 weeks, between May 2012 and April
2014. The Human Studies Facility is approximately 8 miles
southwest of Duke University. Upon arrival on the first
study day, the subject’s medical history was reviewed, vital
signs were assessed, and the subject was outfitted with a
Holter monitor which they would wear for the next 24 h.
The following day, under fasting conditions, the subject
was assessed for biomarkers present in blood, heart rate
variability and repolarization measured by Holter moni-
toring, blood pressure, and endothelial function measured
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by brachial artery ultrasound and pulse wave analysis. To
minimize day-of-week effects, each subject was always
studied on the same 2 days of the week. Written
informed consent was given by all participants prior to
enrollment, and the study was approved by the Duke
University Institutional Review Board, the University
of North Carolina at Chapel Hill Institutional Review
Board, and the U.S. Environmental Protection Agency
(EPA) Human Protocols Office.
Clinical measurements
Peripheral venous blood samples
Approximately 50 mL of venous blood was obtained
from each subject. A portion of fresh blood was sent to
a clinical laboratory (Lab Corp., Burlington, NC, USA)
for analysis of differential blood cell counts, as well as
quantification of blood lipids. The remaining blood sam-
ples were stored at −80 °C prior to analysis.
Commercially available multiplex kits (Meso Scale
Diagnostics, Gaithersburg, MD) were used to quantify
levels of C-reactive protein (CRP), serum amyloid A
(SAA), soluble intercellular adhesion molecule (sICAM),
soluble vascular adhesion molecule (sVCAM), interleukin
1-beta (IL-1β), interleukin-6 (IL-6), interleukin-8 (IL-8),
and tumor necrosis factor-alpha (TNF-α) (SECTOR®
Imager 2400, Meso Scale Diagnostics). All other assays
(D-dimer, tissue plasminogen factor (tPA), von Willebrand
factor (vWF), plasminogen activator inhibitor-1 (PAI-1),
and plasminogen) were measured using MesoScale multi-
array plates as per manufacturers’ instructions.
Brachial artery ultrasound
Based on the guidelines by Corretti et al. [21], brachial
artery ultrasound (BAU) was measured to evaluate endo-
thelial cell function using a 15 MHz transducer inter-
faced with an Acuson Sequoia 512 ultrasound machine
(Siemens Healthcare, Malvern, PA, USA). As described
earlier [22], resting blood pressure and the diameter of
the brachial artery were measured at baseline, and the
baseline diameter of the brachial artery (BAD) was also
measured during reactive hyperemia for quantification
of flow-mediated dilatation (FMD).
With the volunteer laying supine, a pneumatic tourni-
quet was placed around the right arm distal to the bra-
chial artery. R-wave gated baseline images of the artery
were acquired after 15 min. The cuff was then inflated
to a pressure of 50 mmHg above the participant’s SBP
for 5 min. The cuff was abruptly deflated to cause a
hyperemia reaction. Images of the brachial artery were
acquired for 90 s, stored in a digital format, and subse-
quently analyzed. Arterial diameter from the lumen-
intimal interfaces of the proximal and distal walls was
measured using customized software (Brachial Tools,
Medical Imaging Applications, LLC, Coralville, IA,
USA). Data from at least three consecutive end-diastolic
frames were averaged for each baseline measurement
and from at least three frames at maximal dilatation
during reactive hyperemia. Changes in diameter caused
by reactive hyperemia (endothelium-dependent vasodila-
tation) were expressed as a percent change in vessel
diameter from their respective baselines.
Pulse wave analysis
Arterial elasticity was measured by the contour analysis
of the arterial pressure waveform (pulse wave) using the
HDI/PulseWave CR-2000 Research Cardiovascular Pro-
filing system (Hypertension Diagnostics Inc., Eagan,
MN, USA) as previously described [22]. Three assess-
ments of arterial compliance were obtained and aver-
aged. Measurements included the large-artery elasticity
index (LAEI) and small-artery elasticity index (SAEI).
The system gathered and analyzed a 30-s analog tracing
of the radial artery waveforms digitized at 200 samples/s.
A beat determination was made during the 30-s time
period to determine systole, peak systole, onset of dia-
stole, and end of diastole. Representative averaged wave-
forms of individual beats were analyzed using a parameter-
estimating algorithm [23] to fit a multiplexed model [24].
Endothelial dysfunction is associated with decreasing elas-
ticity indices.
Holter monitoring
Continuous ambulatory electrocardiograms (ECGs) were
placed on each subject during the first day of each week’s
two-day visit and were collected for 24 h periods using a
Mortara H12+ 12-Lead ECG Recorder (Mortara Instru-
ment Co., Milwaukee, WI) sampling at 180 Hz. During
the second day, the subjects were asked to recline in a
dark place, and data was collected for 30 min. A trained
nurse manually inspected and edited the sequence of ECG
complexes to ensure proper labeling. RR-intervals that
were more or less than 20% of the previous RR-interval
were defined as abnormally long or short intervals and
were interpolated using Mortara algorithms. Subsequent
heart rate variability (HRV) indices for both the time and
frequency domains were calculated.
Time-domain measurements were calculated over the
full 24 h span, while a 5 min segment during the end of
the resting period was used for the calculation of the
frequency-domain and repolarization indices. Time-
domain measurements included standard deviation of
the normal-to-normal (SDNN) and root-mean squared
of successive differences (rMSSD). Frequency-domain
measurements included low frequency (LF, 0.04–
0.15 Hz), high frequency (HF, 0.15–0.40 Hz), low-to-
high frequency power (LF:HF), and the sum of the
power spectrum density (PSD).
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Markers of cardiac repolarization were assessed by
measuring the QT interval, which is it the measurement
from the beginning of the QRS complex to the end of
the T wave; we corrected the QT interval for heart rate
(QTc). T wave complexity was measured in each beat by
principal component analysis based on all 12 leads and
averaged. QRS complexity and P wave complexity were
calculated with Mortara software.
Air pollution and meteorological measurements
Daily 24 h measurements of ozone and PM2.5 were
calculated from hourly pollutant data averaged between
9 AM to 8 AM; this data was obtained from a central air
monitoring station (Millbrook) located approximately
44 km (27 miles) from the EPA Human Studies Facility
and operated by the State of North Carolina. Two visits
used pollutant data from a different central monitor
(Durham Armory) due to missing values; this location
was approximately 18 km (11 mi) from the EPA Human
Studies Facility. Concentrations were obtained for each
clinic day, as well as for 4 days prior. Daily temperature,
relative humidity, and pressure were also obtained from
the Millbrook central monitoring station.
Statistical analysis
The study was conducted as a panel study with four to
ten repeated measurements per participant. Thus, every
subject acted as his/her own control, limiting the need
for an adjustment for subject characteristics. Data were
analyzed using the R statistical package (Version 3.3.0)
using both a single (ozone) and two-pollutant (ozone
and PM2.5) model. For the analyses, we used additive
mixed models with a random subject effect that dimin-
ished the need for an adjustment for subject character-
istics. Daily temperature and relative humidity
corresponding to the lag of the pollutant were selected
as covariates a priori, and we adjusted for seasonal
trends using a natural spline. To determine the add-
itional benefit of including a five-day average of baro-
metric pressure as a covariate, models including and
excluding the pressure term were compared on the
basis of Akaike Information Criterion (AIC) and
changes to the ozone coefficient. For this work, the
ozone exposure was considered either as an immediate
(lag 0), delayed (lag 1 to 4), or cumulative (5 day mov-
ing average, 5dMA) linear effect, similar to our previ-
ously published work [25]. All outcomes were log
transformed prior to analysis, are reported as percent
change from the mean of the measured outcome per
unit interquartile range (IQR) of exposure, and statis-
tical significance was set at p < 0.05 for the percent
change from the mean of the measured outcome per
unit IQR of exposure.
Results
Of the 15 participants that were recruited for this study,
two completed less than three study sessions and were
not included in the final analysis (Table 1). The subjects’
ages ranged from 53 to 68 years. Although inclusion in
the study was open to both men and women, only men
responded to advertisements and successfully passed the
screening criteria. Most of the participants were taking
medication: six subjects reported taking medication for
diabetes, nine subjects were taking beta blockers, and
twelve were taking HMG CoA reductase inhibitors (sta-
tins). Of the 13 subjects, five had experienced a previous
myocardial infarction and nine had hypertension.
Although subjects were excluded for being current
smokers or smoking more than one pack of cigarettes 1
year before enrolling in this study, seven participants
had a past history of smoking. Nine participants com-
pleted ten visits, two participants completed nine visits,
one participant completed five visits, and one participant
completed four visits. Altogether there were 117 expos-
ure days analyzed (Fig. 1a).
Air pollution and meteorological measurements are
shown in Table 2. Ozone concentrations during the en-
tire study period (May 30, 2012-April 29, 2014) ranged
from 0.002 to 0.063 ppm, with an interquartile range of
0.014 ppm and a mean value of 0.026 ± 0.010 ppm.
Ozone concentrations at the Millbrook and Armory
central monitoring stations were highly correlated
Table 1 Participant characteristics (n = 13)
Characteristics (n = 13) Value
Age (years) 63 (53–68)
Males 13 (100%)
Race
Caucasian 10 (77%)
Black 3 (23%)
Current health status
BMI (kg/m2) 31 (26–38)
Systolic blood pressure 130 (102–141)
Diastolic blood pressure 77 (65–90)
Asthma 1 (8%)
Current medication use
Diabetes medication 6 (46%)
Beta blockers 9 (69%)
Statins 12 (92%)
Past health status
Previous MI 5 (38%)
Previous hypertension 9 (69%)
Past smokers 7 (54%)
Values expressed as either mean (range) or number (%). BMI body mass index,
MI myocardial infarction
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(Spearman correlation coefficient = 0.92; p < 0.0001).
PM2.5 mass concentrations during the study period
ranged from 1.0 to 28.2 μg/m3, with an interquartile
range of 5.4 μg/m3 and a mean value of 10.9 ± 4.5 μg/
m3. Ozone and PM2.5 concentrations were not signifi-
cantly correlated (Spearman correlation coefficient = 0.05;
p = 0.19). Temperature and humidity fluctuations during
the study period ranged from 18.4 to 91.1 °F and 26.5 to
96.3%, respectively. In this paper, we describe the associ-
ation of ozone with various cardiovascular outcomes,
using both a one- (ozone) and two-pollutant (ozone and
PM2.5) model. The results for all endpoints are shown in
Additional file 1: (Table S1). Associations between PM2.5
and cardiovascular outcomes will be described elsewhere.
Figure 1 shows the daily ozone concentrations during the
nearly two-year duration of the study and at the date of
each subject’s clinical visits, which were spread out across
various seasons to get a range of ozone concentrations for
this work. The maximum observed ozone and PM2.5 con-
centrations during the study duration were below the EPA
National Ambient Air Quality Standards, which are
0.070 ppm for ozone (8 h) and 35 μg/m3 for PM2.5 (24 h).
Large artery elasticity index (LAEI) decreased with
increasing ozone concentrations (Fig. 2). There was a
significant 19.5% decrease for the 5 day moving average
(95% confidence intervals (CI) = −34.0, −1.7; p = 0.03),
and a borderline significant 11.7% decrease with a lag of
4 days (95% CI = −22.1, 0.0; p = 0.05). LAEI is a measure
of arterial compliance, defined as the ability of an artery
to expand and recoil with cardiac pulsation and
relaxation. A decrease in compliance results in a stiffen-
ing of the artery and is a risk factor for atherosclerosis.
For SAEI, there was a trend for an increase with lags of
2 and 3 days. There was a 2.5% decrease in the baseline
diameter of the brachial artery (BAD) associated with
ozone with a 2 day lag (95% CI = −5.0, 0.1; p = 0.06).
This was counterbalanced with a significant 3.5% in-
crease with a 4 day lag (95% CI = 1.2, 5.9; p < 0.01;
Fig. 3). No significant changes were observed for FMD
(Additional file 1: Table S1). There was also a 3.3% mar-
ginally significant decrease in diastolic blood pressure
with a 2 day lag (95% CI = −6.6, 0.2; p = 0.07). Similar
decreases in blood pressure associated with ozone expo-
sures have been reported by others [26].
Factors attributed to clotting and fibrinolysis included
tissue plasminogen factor (tPA), plasminogen activator
inhibitor-1 (PAI-1), von Willebrand factor (vWF), plas-
minogen, and D-dimer. Ozone was associated with a
6.6% increase in tPA with a 3 day lag (95% CI = 0.4,
13.2; p = 0.04), and a near-significant 6.3% increase with
a 4 day lag (95% CI = −0.1, 13.1; p = 0.05; Fig. 4), per
IQR of ozone. A 20.0% increase in PAI-1 with a 2 day
lag (95% CI = 0.8, 42.8; p = 0.04), and a 40.5% increase
with a 5 day moving average were also observed (95%
CI = 8.7, 81.6; p = 0.01); there were near-significant in-
creases with 3 (95% CI = −2.3, 35.0; p = 0.09) and 4
(95% CI = −2.1, 35.6; p = 0.09) day lags. PAI-1 and tPA
are associated the fibrinolysis pathway. No significant
changes were observed for von Willebrand factor, plas-
minogen, and D-dimer (Additional file 1: Table S1).
Fig. 1 Patient visits and mean daily ozone concentrations (ppm) between May 30, 2012-April 29, 2014. a Data points represent the days the patients
visited the Human Studies Facility. b Daily 24-h ozone (ppm) concentrations (9 AM to 8 AM) calculated from the Millbrook central monitor
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The number of neutrophils and monocytes, as well as
the concentrations of IL-6, IL-8, TNF-α, CRP, SAA,
sICAM, and sVCAM, were measured. Per IQR of ozone,
an 8.7% increase in the number of neutrophils was ob-
served with a 1 day lag (95% CI = 1.5, 16.4; p = 0.02), an
8.4% increase was observed with a 2 day lag (95%
CI = 1.0, 16.3; p = 0.03), and a near-significant 11.2%
increase was observed with the 5 day moving average
(95% CI = −0.2, 23.9; p = 0.05; Fig. 5). Ozone was also
associated with a 10.2% increase in the number of
monocytes following 1 day lag (95% CI = 1.0, 20.1;
p = 0.03). For IL-6, increases in 11.9% (95% CI = −1.3,
27.0; p = 0.08) and 15.9% (95% CI = 3.6, 29.6; p = 0.01)
per IQR of ozone were observed at 2 and 3 day lags,
respectively; and a 5.9% increase in TNF-α was found
following a 2 day lag (95% CI = −0.9, 13.2; p = 0.09;
Fig. 5). Finally, a 9.6% decrease in sVCAM was associ-
ated with increases 2 days prior to the collection of bio-
logical specimens (95% CI = −17.2, −1.2; p = 0.03). No
significant associations with ozone were observed for IL-
8, CRP, SAA, or sICAM (Additional file 1: Table S1).
As shown in Additional file 1: (Table S1), ozone was not
significantly associated with changes in heart rate variabil-
ity as measured by the standard deviation of the beat-to-
beat interval (SDNN), root-mean squared of successive
differences between adjacent NN intervals (rMSSD), low
frequency domain (LF), high frequency domain (HF), and
sum of the power spectrum density (PSD). Ozone was also
not associated with measurements of repolarization in-
cluding the duration of the QT interval (QTc), or com-
plexity of the P-wave, T-wave, or QRS. We also found no
associations between ozone and changes in lipids, includ-
ing cholesterol, triglycerides, high density lipoprotein
(HDL), or low density lipoprotein (LDL).
To determine if the associations observed with ozone
were confounded by PM2.5, a two-pollutant model was
used (Additional file 2: Table S2). For those outcomes
that were associated with ozone in the single pollutant
model, minimal (less than 10%) changes were observed
in the effect estimates when PM2.5 was included in the
two-pollutant model, suggesting that the effects
observed for ozone were specific to ozone and inde-
pendent of PM2.5. In some cases, confidence intervals
were slightly widened in the two-pollutant model, while
in others they were slightly narrowed. Because of the
limited sample size in this study, effect modification by
age, gender, medication, and others could not be
determined.
Table 2 Average daily ozone concentrations during study period (May 30, 2012-April 29, 2014)
Mean ± SD Minimum 25th percentile Median 75th percentile Maximum IQR
Ozone (ppm) 0.026 ± 0.010 0.002 0.019 0.025 0.033 0.063 0.014
PM2.5 (μg/m
3) 10.9 ± 4.5 1.0 7.8 9.9 13.2 28.2 5.4
Temperature (°F) 59.1 ± 16.0 18.4 45.2 60.1 74.0 91.1 28.8
Relative humidity (%) 67.9 ± 14.2 26.5 57.9 70.0 78.4 96.3 20.5
Barometric pressure (hPa) 1018.2 ± 6.0 1001.4 1014.0 1018.0 1021.9 1036.4 7.9
IQR interquartile range, PM particulate matter, SD standard deviation
Fig. 2 Percent changes of elasticity indices with ambient ozone
concentrations. Effect estimates (95% CI) were log-transformed,
correspond to changes per IQR of ozone, and were adjusted for
season, temperature, and humidity. IQR = interquartile range;
LAIE = large artery elasticity index; SAEI = small artery elasticity
index; 5dMA = 5 day moving average
Fig. 3 Percent changes of endothelial function with ambient ozone
concentrations. Effect estimates (95% CI) were log-transformed,
correspond to changes per IQR of ozone, and were adjusted for
season, temperature, and humidity. Effect estimates for FMD were
also adjusted for the 5dMA barometric pressure. IQR = interquartile
range; FMD = flow-mediated dilatation; BAD = baseline artery
diameter; 5dMA = 5 day moving average
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Discussion
In this panel study of a population with stable CAD, we
observed associations between ambient ozone concen-
trations and changes in biological pathways involved in
inflammation, fibrinolysis, and endothelial cell function.
These changes were still evident when controlling for
PM2.5 concentrations, suggesting that these results were
independent of PM2.5 exposures.
Endothelium-derived mediators as well as vascular
smooth muscle function regulate vascular tone structure,
which can influence arterial stiffness and diameter. Arterial
stiffness is the reduced ability of an artery to contract and
expand during pressure changes [27]. One of the parame-
ters used to describe arterial stiffness is arterial compliance,
which is the measure of volume changes in a vessel in re-
sponse to changes in arterial pressure [27]. Studies have
found inverse associations between arterial compliance and
age, glucose levels, smoking, hypertension, and metabolic
syndrome [28, 29]. In the current study, we observed asso-
ciations between ozone and a decrease in LAEI, indicating
reduced arterial compliance. Past studies looking at other
measures of arterial compliance have also reported nega-
tive associations with ozone exposure in elderly males as
part of the VA Normative Aging Study Cohort [30] and in
healthy adults [31]. In addition to LAEI, we observed an
association between ozone and a decreased diameter of the
brachial artery. Vasoconstriction caused by arterial narrow-
ing can increase blood pressure, which could result in ad-
verse outcomes in susceptible populations such as those
with hypertension.
In this current work, we also found associations
between ozone and increased levels of two critical com-
ponents of the fibrinolysis pathway: tPA and PAI-1. The
fibrinolytic pathway degrades blood clots that are
formed during the normal course of living [32], and any
process that inhibits this pathway increases the risk for
adverse events associated with coagulation. When bound
with tPA, plasminogen is converted to plasmin, which
then degrades fibrin and dissolves clots. PAI-1 inhibits
tPA, and increasing concentrations of PAI-1 are associ-
ated with decreases in fibrinolysis. Concentrations of
PAI-1 in plasma are much higher than tPA, and assays
quantifying tPA levels generally reflect the concentra-
tions of tPA complexed with PAI-1 [33]. For this reason,
increasing concentrations of tPA also can indicate
reduced fibrinolysis [33]. Similar increases in tPA were
observed in a previously conducted controlled human
exposure study of ozone and clean air in healthy, young
participants [11]. In a panel study of 76 young, healthy
students in Taipei, increases in PAI-1 and tPA were
found with 1- to 3- day averages of ambient ozone con-
centrations in both a single- and multi-pollutant model
[34]. Taken as a whole, our data suggest that ozone can
negatively impact the fibrinolysis pathway.
Fig. 4 Percent changes of clotting and fibrinolysis factors with ambient
ozone concentrations. Effect estimates (95% CI) were log-transformed,
correspond to changes per IQR of ozone, and were adjusted for season,
temperature, and humidity. IQR = interquartile range; tPA = tissue
plasminogen factor; PAI-1 = plasminogen activator inhibitor-1;
5dMA = 5 day moving average
Fig. 5 Percent changes of inflammatory factors with ambient ozone
concentrations. Effect estimates (95% CI) were log-transformed,
correspond to changes per IQR of ozone, and were adjusted for
season, temperature, and humidity. a Percent changes in the
number of neutrophils and monocytes; b Percent changes in IL-
6 and TNF-α. IQR = interquartile range; IL = interleukin; TNF = tumor
necrosis factor; 5dMA = 5 day moving average
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A large body of research has shown associations
between ozone and cellular and soluble makers of pul-
monary inflammation [35, 36]. In a previously con-
ducted controlled ozone study, increases in the
systemic inflammatory markers IL-1β, IL-6, and TNF-
α were observed 24 h following ozone exposures com-
pared to baseline values [12]. In a separate controlled
study, plasma levels of IL-6 were elevated in both
obese and non-obese non-smoking women after acute
ozone exposures [37]. When 45 non-smoking adults
enrolled in a panel study to assess the association of
ambient air pollution and systemic inflammation,
positive associations between IL-6 and ozone were ob-
served [38]. In this current work, we report an associ-
ation between ozone and increased levels of cellular
and soluble markers of vascular inflammation, as well
as associations between ozone and increased numbers
of monocytes, neutrophils, and two markers of inflam-
mation: IL-6 and TNF-α. Clinically, increases in
plasma IL-6 and TNF-α have been associated with car-
diovascular disease and disease outcomes [39].
Our findings in humans with CAD corroborate some
experimental data from animals exposed to air pollu-
tion. When rats were exposed to 0.50 ppm of ozone for
5 h/day for 2 days, increases in PAI-1 were observed
[40]. However, in contrast, Farraj et al. [41] observed
significant changes in heart rate variability parameters
and blood lipids in spontaneously hypertensive rats
exposed to various ozone concentrations; these
changes were only observed after high ozone expo-
sures (0.8 ppm), and no changes in heart rate variabil-
ity were found following lower exposures (0.2 ppm).
Therefore, it is possible that we did not observe alter-
ations in heart rate variability due to the relatively low
ozone concentration observed in the ambient environ-
ment compared with those used in laboratory studies.
We observed that several of the biological pathways
disrupted by PM2.5 exposures may also be altered by
ozone exposures. For example, we previously reported
decreased levels of LAEI to be associated with PM2.5 in
type 2 diabetics [22]. Additionally, increases in tPA [42]
and systemic pro-inflammatory cytokines [43] are associ-
ated with particle exposures.
In contrast with studies looking at cardiovascular
changes or blood lipids associated with PM2.5 exposures
[25, 44], we did not observe associations between ozone
and any marker of heart rate variability or repolarization,
or in blood lipids. It is possible that medication use pre-
vented us from seeing these effects. For example, 70% of
the participants were taking beta blocker medication
which is known to interfere with HRV analysis [45], and
a similar proportion were taking statin medications,
which may impact air pollution-induced increases in
blood lipids.
Lag effects may differ between ozone and PM2.5 as
well. In a previous panel study of diabetic patients,
we observed an association between PM2.5 and in-
flammatory changes at lags 2–3, but endothelial func-
tion changes occurred with a 0 day lag [22, 25]. In
the current study, we did not observe rapid changes
(i.e. those occurring with a 0 or 1 day lag) associated
with ozone, with the exception being systemic inflam-
matory mediators. This is consistent with observations
of rapid responses in human systemic inflammatory
markers in laboratory-controlled conditions [11].
Similarly, Bind et al. [46] observed ozone-induced re-
sponses in pro-inflammatory mediators as early as 4
and 24 h, which then decreased in intensity at later
time points.
There are several strengths in this study. Unlike prior
studies, we examined a significantly at-risk population –
those with active CAD. Further, given the recent interest
in examining the effects of multiple pollutants simultan-
eously, we used a two-pollutant model to adjust for
PM2.5 concentrations, observing ozone effects independ-
ent of PM2.5. We also studied the time-course of effects
at several temporal lags relative to exposure. Last, via
the repeated measures study design, we accounted for
both between- and within-subject variability.
There were also several limitations. It is possible that
our study may suffer from selection bias; inclusion in
the CATHGEN cohort could be as a result of referral
bias, enrollment biases, and those related to socioeco-
nomic status and other unmeasured confounders. We
also used central monitoring stations for our exposures,
which may result in exposure misclassification. All of
the subjects were taking at least one cardiovascular dis-
ease medication, which could have affected our ability to
detect ozone-associated differences. Further, given the
relatively small sample size, we were not able to assess
for effect modification such as genotype, body mass
index, and medication [22, 25].
Conclusions
In this panel study of ambient air pollution exposure in
a population with extant coronary heart disease, we ob-
served ozone-associated alterations in several pathways
associated with cardiovascular morbidity and mortality:
fibrinolysis, systemic inflammation, and vascular reactiv-
ity. The effects remained strong after controlling for
PM2.5 concentrations. Future work will compare these
effects with effects associated with PM2.5 in the same co-
hort. This study contributes new information regarding
the mechanisms underlying the effects of ozone on car-
diovascular risk. The observed effects were found at am-
bient concentrations below the EPA National Ambient
Air Quality Standards for both ozone and PM2.5.
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Additional files
Additional file 1: Table S1. Percent changes of measured factors with
ambient ozone concentrations. Effect estimates (95% CI) were log-
transformed, correspond to changes per IQR of ozone, and were ad-
justed for season, temperature, and humidity. Effect estimates for SumPSD,
LF:HF, LF, HF, FMD, and CRP were also adjusted for the 5dMA barometric
pressure. LAIE = large artery elasticity index; SAEI = small artery elasticity index;
FMD = flow-mediated dilatation; BAD = baseline artery diameter; SBP = systolic
blood pressure; DBP = diastolic blood pressure; tPA = tissue plasminogen
factor; PAI-1 = plasminogen activator inhibitor-1; vWF = von Willebrand factor;
IL = interleukin; TNF = tumor necrosis factor; CRP = C-reactive protein;
SAA = serum amyloid A; sICAM = soluble intercellular adhesion molecule;
sVCAM = soluble vascular adhesion molecule; HDL = high density lipoprotein;
LDL = low density lipoprotein; LF = low frequency; HF = high frequency;
PSD = power spectrum density; SDNN = standard deviation of the normal-
to-normal; rMSSD = root-mean squared of successive differences. *p value <
0.10 for the percent change from the mean of the measured outcome per
unit IQR of exposure, **p value < 0.05 for the percent change from the mean
of the measured outcome per unit IQR of exposure. (DOCX 21 kb)
Additional file 2: Table S2. Percent changes of measured factors with
ambient ozone and PM2.5 concentrations using a two-pollutant model. Effect
estimates (95% CI) were log-transformed, correspond to changes per IQR of
the corresponding pollutants, and were adjusted for season, temperature,
and humidity. Effect estimates for FMD were also adjusted for the 5dMA
barometric pressure. LAIE = large artery elasticity index; SAEI = small artery
elasticity index; FMD = flow-mediated dilatation; BAD = baseline artery diameter;
IL = interleukin; TNF = tumor necrosis factor; tPA = tissue plasminogen factor;
PAI-1 = plasminogen activator inhibitor-1. *p value < 0.10 for the percent
change from the mean of the measured outcome per unit IQR of exposure, **p
value < 0.05 for the percent change from the mean of the measured outcome
per unit IQR of exposure. (DOCX 21 kb)
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